Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 29, 2011. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 600,000 Ordinary shares of 25 pence each.
- Purchase Date: November 29, 2011.
- Price Range: Highest price paid was 1,372.5 pence per share; lowest price paid was 1,357.5 pence per share.
- Treasury Holdings (Settled): 527,332,927 shares (9.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 529,082,927 shares (10.49% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,045,814,284 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 600,000 shares for Treasury. This transaction increased the proportion of shares held in Treasury to 9.46% of issued capital and 10.49% of total voting rights when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (527,332,927 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights represented by Treasury shares (10.49% including unsettled).
- Check the denominator for shareholder notification thresholds, which is 5,045,814,284 shares in issue.
- Review the price paid per share (1,357.5 to 1,372.5 pence) against market prices on November 29, 2011.